Tocilizumab dose of 8mg/kg up to a maximum dose of 800mg to be administered as a single dose only. Tocilizumab is administered as an intravenous infusion over 60 minutes on day -1 of conditioning.

3 trials

Sponsors

Royal Brisbane and Women's Hospital

Phase 1

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD)

RecruitingACTRN12612000726853

Royal Brisbane and Women's Hospital

Start: 2012-01-13Target: 48Updated: 2020-01-13

Phase 2

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD)

RecruitingACTRN12614000212651

Royal Brisbane and Women's Hospital

Start: 2014-04-04Target: 18Updated: 2020-01-13

Phase 3

Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial

RecruitingACTRN12614000266662

Royal Brisbane and Women's Hospital

Start: 2014-04-04Target: 110Updated: 2020-01-13

Related Papers

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Blood2023-11-021 citations

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

2014-11-14178 citations